Chengyi Pharmaceutical : The net profit for the half year of 2023 is approximately 90.6 million yuan, an increase of 39.48% year-on-year

Chengyi Pharmaceutical (SH 603811, closing price: 11.14 yuan) released a semi annual performance report on the evening of August 23, stating that its operating revenue for the first half of 2023 was approximately 321 million yuan, an increase of 0.85% year-on-year; The net profit attributable to shareholders of the listed company is approximately 90.6 million yuan, an increase of 39.48% year-on-year; The basic earnings per share were 0.28 yuan, an increase of 40% year-on-year.

From January to June 2023, the operating revenue of Chengyi Pharmaceutical was composed of pharmaceutical manufacturing industry accounting for 99.84%.

The chairman of Chengyi Pharmaceutical is Yan Yiyi, male, 74 years old, with a college education background; The general manager is Zhao Chunjian, male, 46 years old, with a bachelor's degree background.

As of press release, the market value of Chengyi Pharmaceutical is 3.6 billion yuan.

Article source:Daily Economy

Original News Title: Chengyi Pharmaceutical : Net profit for the half year of 2023 is approximately 90.6 million yuan, an increase of 39.48% year-on-year